Sales & Earnings
The company announced positive Phase II results for the JAK1/TYK2 inhibitor in cutaneous sarcoidosis, which has no approved treatments.
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
The drugmaker highlighted a wide array of development programs in its fourth quarter earnings, including moving tirzepatide into multiple inflammatory conditions.
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
The drugmaker’s sales grew by more than 40% for the fourth quarter and fiscal year 2025, with tirzepatide accounting for more than half of annual sales.
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
The drugmaker announced its fourth quarter and full-year results for 2025, highlighting significant revenue opportunities ahead across indications.
C&D starts 2026 with expectations to boost sales of latest acquisition, Touchland scented hand sanitizer, after halting sales of Flawless hair removal/nail care and Waterpik showerhead products and selling Spinbrush power toothbrush brand as well vitafusion and L’il Critter gummy supplement lines.
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.